Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 247

1.

Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia.

Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA.

J Clin Invest. 2003 Mar;111(5):649-58.

2.

Twin pregnancy and the risk of preeclampsia: bigger placenta or relative ischemia?

Bdolah Y, Lam C, Rajakumar A, Shivalingappa V, Mutter W, Sachs BP, Lim KH, Bdolah-Abram T, Epstein FH, Karumanchi SA.

Am J Obstet Gynecol. 2008 Apr;198(4):428.e1-6. doi: 10.1016/j.ajog.2007.10.783. Epub 2008 Jan 14.

PMID:
18191808
3.

Soluble fms-like tyrosine kinase-1 and soluble endoglin in HIV-associated preeclampsia.

Govender N, Naicker T, Rajakumar A, Moodley J.

Eur J Obstet Gynecol Reprod Biol. 2013 Sep;170(1):100-5. doi: 10.1016/j.ejogrb.2013.05.021. Epub 2013 Jun 24.

PMID:
23806447
4.

Endometrial VEGF induces placental sFLT1 and leads to pregnancy complications.

Fan X, Rai A, Kambham N, Sung JF, Singh N, Petitt M, Dhal S, Agrawal R, Sutton RE, Druzin ML, Gambhir SS, Ambati BK, Cross JC, Nayak NR.

J Clin Invest. 2014 Nov;124(11):4941-52. doi: 10.1172/JCI76864. Epub 2014 Oct 20.

5.

[THE ROLE OF ANGIOGENIC FACTORS IN THE DIAGNOSTICS OF PREGNANCY COMPLICATED WITH PREECLAMPSIA].

Tagiyeva I, Aliyeva S, Bagirova S, Shamsadinskaya N, Agaeva K.

Georgian Med News. 2017 Jul-Aug;(268-269):35-38. Russian.

PMID:
28820409
6.

Serum sFlt1:PlGF ratio, PlGF, and soluble endoglin levels in gestational proteinuria.

Ohkuchi A, Hirashima C, Matsubara S, Suzuki H, Takahashi K, Usui R, Suzuki M.

Hypertens Pregnancy. 2009 Feb;28(1):95-108. doi: 10.1080/10641950802419895.

PMID:
19165674
7.

In vivo uteroplacental release of placental growth factor and soluble Fms-like tyrosine kinase-1 in normal and preeclamptic pregnancies.

Holme AM, Roland MC, Henriksen T, Michelsen TM.

Am J Obstet Gynecol. 2016 Dec;215(6):782.e1-782.e9. doi: 10.1016/j.ajog.2016.07.056. Epub 2016 Aug 5.

PMID:
27503620
8.

Circulating concentrations of sFlt1 (soluble fms-like tyrosine kinase 1) in fetal and maternal serum during pre-eclampsia.

Staff AC, Braekke K, Harsem NK, Lyberg T, Holthe MR.

Eur J Obstet Gynecol Reprod Biol. 2005 Sep 1;122(1):33-9.

PMID:
15935542
9.

KRYPTOR-automated angiogenic factor assays and risk of preeclampsia-related adverse outcomes.

Salahuddin S, Wenger JB, Zhang D, Thadhani R, Karumanchi SA, Rana S.

Hypertens Pregnancy. 2016 Aug;35(3):330-45. doi: 10.3109/10641955.2016.1148162. Epub 2016 Mar 30.

PMID:
27028795
10.

Hydrogen sulfide attenuates sFlt1-induced hypertension and renal damage by upregulating vascular endothelial growth factor.

Holwerda KM, Burke SD, Faas MM, Zsengeller Z, Stillman IE, Kang PM, van Goor H, McCurley A, Jaffe IZ, Karumanchi SA, Lely AT.

J Am Soc Nephrol. 2014 Apr;25(4):717-25. doi: 10.1681/ASN.2013030291. Epub 2013 Dec 12.

11.

Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria.

Sugimoto H, Hamano Y, Charytan D, Cosgrove D, Kieran M, Sudhakar A, Kalluri R.

J Biol Chem. 2003 Apr 11;278(15):12605-8. Epub 2003 Jan 21.

12.

Placental growth factor and soluble FMS-like tyrosine kinase-1 in early-onset and late-onset preeclampsia.

Wikström AK, Larsson A, Eriksson UJ, Nash P, Nordén-Lindeberg S, Olovsson M.

Obstet Gynecol. 2007 Jun;109(6):1368-74.

PMID:
17540809
13.

Placental Growth Factor Administration Abolishes Placental Ischemia-Induced Hypertension.

Spradley FT, Tan AY, Joo WS, Daniels G, Kussie P, Karumanchi SA, Granger JP.

Hypertension. 2016 Apr;67(4):740-7. doi: 10.1161/HYPERTENSIONAHA.115.06783. Epub 2016 Feb 1.

14.

Dysregulation of hydrogen sulfide producing enzyme cystathionine γ-lyase contributes to maternal hypertension and placental abnormalities in preeclampsia.

Wang K, Ahmad S, Cai M, Rennie J, Fujisawa T, Crispi F, Baily J, Miller MR, Cudmore M, Hadoke PW, Wang R, Gratacós E, Buhimschi IA, Buhimschi CS, Ahmed A.

Circulation. 2013 Jun 25;127(25):2514-22. doi: 10.1161/CIRCULATIONAHA.113.001631. Epub 2013 May 23.

15.

Soluble Fms-like tyrosine kinase 1 and endothelial dysfunction in the pathogenesis of preeclampsia.

Maynard SE, Venkatesha S, Thadhani R, Karumanchi SA.

Pediatr Res. 2005 May;57(5 Pt 2):1R-7R. Epub 2005 Apr 6. Review.

PMID:
15817508
16.

Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia.

Rana S, Powe CE, Salahuddin S, Verlohren S, Perschel FH, Levine RJ, Lim KH, Wenger JB, Thadhani R, Karumanchi SA.

Circulation. 2012 Feb 21;125(7):911-9. doi: 10.1161/CIRCULATIONAHA.111.054361. Epub 2012 Jan 18.

17.

Relationship between nulliparity and preeclampsia may be explained by altered circulating soluble fms-like tyrosine kinase 1.

Bdolah Y, Elchalal U, Natanson-Yaron S, Yechiam H, Bdolah-Abram T, Greenfield C, Goldman-Wohl D, Milwidsky A, Rana S, Karumanchi SA, Yagel S, Hochner-Celnikier D.

Hypertens Pregnancy. 2014 May;33(2):250-9. doi: 10.3109/10641955.2013.858745. Epub 2013 Dec 4.

PMID:
24304210
18.

Angiogenic factors and preeclampsia.

Tjoa ML, Levine RJ, Karumanchi SA.

Front Biosci. 2007 Jan 1;12:2395-402. Review.

PMID:
17127249
19.

Circulating angiogenic factors in preeclampsia, gestational proteinuria, and preeclampsia superimposed on chronic glomerulonephritis.

Masuyama H, Suwaki N, Nakatsukasa H, Masumoto A, Tateishi Y, Hiramatrsu Y.

Am J Obstet Gynecol. 2006 Feb;194(2):551-6.

PMID:
16458660
20.

Urinary placental growth factor and risk of preeclampsia.

Levine RJ, Thadhani R, Qian C, Lam C, Lim KH, Yu KF, Blink AL, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA.

JAMA. 2005 Jan 5;293(1):77-85.

PMID:
15632339

Supplemental Content

Support Center